Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0088

Scientific exchange · Dr. Emiko Vogel

01 Apr 2026 · Virtual · Dr. Emiko Vogel, Charité Berlin · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0088—

Capture insight from this engagement

Location: Charité Berlin
Therapeutic area: Oncology
Country: Germany
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Elderly / ECOG 2 patients

Scientific content used

VTX core scientific deck v3.2
VOYAGE-1 pivotal data summary

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Scientific exchange with oncology pharmacist at Charité Berlin. Discussed elderly / ecog 2 patients.

Insights captured (1)

Capture insight

INS-0082Medium
Elderly / ECOG 2 patients
Elderly / ECOG 2 patients: practice variation observed reported by oncology pharmacist (DE).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 3
Depth of exchange: 3
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0088

Audit history (0)

All create, update and approval events for this record

No audit events in sample data